PDL Biopharma (NASDAQ:PDLI) Shares Bought by Alps Advisors Inc

Lloyd Doyle
May 17, 2018

The firm has a market capitalization of $423.30 million, a price-to-earnings ratio of 4.43 and a beta of 0.36. About 46,850 shares traded. SAExploration Holdings, Inc. (NASDAQ:SAEX) has declined 77.04% since May 14, 2017 and is downtrending.

The stock of Pdl Biopharma Inc (NASDAQ:PDLI) registered an increase of 0.07% in short interest. Therefore 50% are positive. It dropped, as 18 investors sold PDL BioPharma, Inc. shares while 52 reduced holdings. The stock has "Overweight" rating by PiperJaffray on Thursday, December 22.

Investors sentiment decreased to 1.13 in 2017 Q4. It's down -0.37, from 1.5 in 2017Q3.

According to the recommendations from 1 analysts stock has mean rating of 3 on the shares of Pdl Biopharma Inc (NASDAQ:PDLI). 26 funds opened positions while 53 raised stakes. The investment professionals in our partner's database now possess: 134.59 million shares, up from 131.24 million shares in 2017Q3. 24,444 are owned by Parallax Volatility Advisers Ltd Partnership. Ledyard National Bank reported 1,000 shares. Blackrock Incorporated holds 14.71 million shares or 0% of its portfolio.

More recent PDL BioPharma, Inc.


Several research analysts have commented on PDLI shares. Also Seekingalpha.com published the news titled: "PDL BioPharma's (PDLI) CEO John McLaughlin on Q1 2018 Results - Earnings Call Transcript" on May 11, 2018. (NASDAQ:PDLI). Schwab Charles Invest Incorporated holds 3.13 million shares. Public Employees Retirement Association Of Colorado invested in 0% or 57,000 shares. Spark Investment Management LLC bought a new position in PDL Biopharma in the fourth quarter valued at approximately $142,000. (NASDAQ:PDLI) or 1.36 million shares. Bnp Paribas Arbitrage has invested 0% of its portfolio in PDL BioPharma, Inc. (NASDAQ:PDLI) for 357,181 shares. Hillsdale holds 0.15% of its portfolio in PDL BioPharma, Inc. (NASDAQ:PDLI) for 337,800 shares. Teacher Retirement System of Texas increased its holdings in PDL Biopharma by 312.9% during the fourth quarter.

Pdl Biopharma Inc (NASDAQ:PDLI) has grabbed attention from the analysts, when it saw a value decrease of -0.71% or -0.02 points in the last trading session to close at $2.79. Matarin Capital Management Llc owns 1.04 million shares or 0.22% of their U.S. portfolio.

Shares of Pdl Biopharma Inc (NASDAQ:PDLI) plunged -0.71% or -0.02 to reach at $2.79 during previous trading session. It has outperformed by 27.96% the S&P500. In 2012, PDL began providing alternative sources of capital through royalty monetizations and debt facilities, and in 2016 began acquiring commercial-stage products and launching specialized companies dedicated to the commercialization of these products. The company had revenue of $68.04 million during the quarter. The firm operates through two divisions, Income Generating Assets and Product Sales.

The price-earnings ratio (P/E ratio) is the ratio for valuing a company that measures its current share price relative to its per-share earnings. The company now has a Return on Equity (ROE) of 1.8 and a Return on Investment (ROI) of -2.3.

Analysts are expecting average earnings estimates of $0.09 for the current quarter based on the opinion of 1 analysts, relating to high earnings per share estimates of $0.09 and low estimates of $0.09, however Pdl Biopharma Inc (NASDAQ:PDLI) reported $0.04 earnings per share for the same quarter previous year. Also Nasdaq.com published the news titled: "Investor Expectations to Drive Momentum within Masco, Murphy Oil, NGL Energy Partners LP, PBF Energy, PDL ..." on May 08, 2018.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER